{
    "Trade/Device Name(s)": [
        "Tina-quant Lipoprotein (a) Gen.2 Molarity"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K241220",
    "Predicate Device Reference 510(k) Number(s)": [
        "K122722"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DFC"
    ],
    "Summary Letter Date": "December 18, 2024",
    "Summary Letter Received Date": "December 18, 2024",
    "Submission Date": "January 24, 2025",
    "Regulation Number(s)": [
        "21 CFR 866.5600"
    ],
    "Regulation Name(s)": [
        "Low-density Lipoprotein Immunological Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Lipoprotein (a) [Lp(a)]"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Li-Heparin tube",
        "K2-EDTA tube",
        "K3-EDTA tube",
        "Serum tube",
        "Serum tube with gel separation"
    ],
    "Instrument(s)/Platform(s)": [
        "cobas c systems",
        "cobas c 503 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetric assay",
        "Particle enhanced immunoturbidimetric assay"
    ],
    "Methodologies": [
        "Quantitative immunoturbidimetry"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Tina-quant Lipoprotein (a) Gen.2 Molarity assay for quantitation of Lp(a) in human serum and plasma on cobas c systems.",
    "Indications for Use Summary": "In vitro test for quantitative determination of lipoprotein (a) [Lp(a)] in human serum and plasma on cobas c systems; measurement of Lp(a) aids in evaluating lipid metabolism disorders and assessing atherosclerotic cardiovascular disease risk, used with clinical evaluation and other lipoprotein tests.",
    "fda_folder": "Immunology"
}